Table 3: Adjusted odds of associations between the CES-D (continuous scores) and CVD risk factors (clinical cut-offs) by sex.

Outcome variableWomenMen
CES-D scores (0 to 60 points)CES-D scores (0 to 60 points)
Odds ratio95% confidence interval Odds ratio95% confidence interval

 High SBP 140 or DBP 90 mmHg (or  prior hypertension diagnosis/treatment)5731.161.02, 1.31.022*4941.211.03, 1.43.022*
Abdominal obesity
 High WHR 0.9 ♂ and 0.85 ♀ 5621.14a1.00, 1.29.048*4830.990.85, 1.15.869
 fasting CHOL >240 mg/dL (or treatment)
2680.980.79, 1.22.8762470.940.71, 1.24.652
 Low HDL-C <40 ♂ and <50 ♀ mg/dL 2541.221.03, 1.45.019*2380.910.70, 1.16.438
 High LDL-C: >160 mg/dL2541.090.81, 1.46.5842371.450.97, 2.16.073
 High TG >200 mg/dL 2541.170.81, 1.70.4072391.090.77, 1.55.631
 Fasting GLU 126 mg/dL or prior diabetes  diagnosis/treatment 3210.960.78, 1.18.6772921.050.79, 1.40.751
High inflammation
 High hsCRP 3 mg/L 2540.980.81, 1.18.8452381.160.89, 1.50.269

Odds ratios for outcome variables are based on a 5-unit change in CES-D score.
Significance for the CES-D in models: * ; = .07. aThe confidence interval includes 1 due to rounding.
Data shown are for logistic regressions after adjustments for age, poverty status, and BMI; histories of CVD, hypertension, and/or diabetes; medication use (antidiabetes, antihypertensive, cholesterol reduction, anti depressants, and hormone replacement therapy); menopausal status; lifetime histories of smoking and drug use; and alcohol use in past week. (Exceptions: covariates BMI, history of hypertension/antihypertensive medications, history of diabetes/antidiabetes medication, and cholesterol-reduction medication were omitted from the models for WHR, hypertension, diabetes, and hypercholesterolemia, resp. Menopause status and hormone replacement therapy were omitted from models for men.)